Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy.

Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy.

Publication date: Feb 25, 2019

Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.

Concepts Keywords
Abstinence Health
Adverse Drug Reaction Vasectomy
Allergic Reaction Investigational treatment
Allergies Accident stroke
ALT Medication Dyspnea
Anaphylaxis Hypersensitivity
ANC Merkel Carcinoma
AST Active inflammatory bowel
Autoimmune Contraception
Bilirubin Organ transplant
Biopsy Immunosuppression
BioScience Oxygen therapy
Blood Treatment of cancer
Bowel Requirements protocol
Carcinoma Checkpoint inhibitor
Cardiac Arrhythmia Pembrolizumab
Cardiovascular Disease Prostate cancer
Cerebrovascular Accident Avelumab
Clinical Trial RTT
Combination Therapy Cancer treatments
Condom Breakthrough therapy
Congestive Heart Failure Merck
Contraception Clinical medicine
Contraindicate Tumor
Corticosteroids Cardiac arrhythmia
Diaphragm Unstable angina
Diastolic Requirements protocol
Dose Equivalent
Dyspnea
FDA
Histologically
HIV
Hypersensitivity
Hypertension
IEC
Immunosuppression
Informed Consent
Intrauterine Devices
Investigational Drug
IRB
IUDs
Lesion
Liver
Lupus Erythematosus
Lymphoma
Malignancy
MCC
Metastases
Metastatic
Methylprednisolone
Myocardial Infarction
Nursing
Organ
Oxygen Therapy
Phase II
Platelet Count
Prostate Cancer
Protocol
Rheumatoid Arthritis
SGOT
SGPT
Spermicide
Steroid
Steroids
Stroke
Surgical Sterilization
Syndrome
Systolic
Testosterone
Tubal Ligation
Tumor
Ulcerative Colitis
Unstable Angina
Vasectomy

Semantics

Type Source Name
drug DRUGBANK Avelumab
gene UNIPROT ANKH
drug DRUGBANK MCC
gene UNIPROT AKR1A1
gene UNIPROT ARMC9
disease MESH Merkel Cell Carcinoma
disease DOID Merkel Cell Carcinoma
drug DRUGBANK Pembrolizumab
disease MESH tumor
pathway BSID Release
disease MESH concomitant disease
disease MESH autoimmune disease
disease DOID autoimmune disease
disease DOID lupus erythematosus
disease MESH rheumatoid arthritis
disease DOID rheumatoid arthritis
pathway BSID Rheumatoid arthritis
disease MESH lymphoma
disease DOID lymphoma
disease MESH inflammatory bowel disease
disease DOID inflammatory bowel disease
disease MESH ulcerative colitis
disease DOID ulcerative colitis
gene UNIPROT SLC17A5
disease MESH metastases
gene UNIPROT CCL27
gene UNIPROT ATRNL1
gene UNIPROT NAT10
gene UNIPROT ALPP
gene UNIPROT SLPI
gene UNIPROT ASRGL1
gene UNIPROT PDLIM3
disease MESH hypertension
disease DOID hypertension
disease MESH cerebrovascular accident
disease DOID cerebrovascular accident
disease MESH myocardial infarction
disease DOID myocardial infarction
disease MESH unstable angina
disease DOID unstable angina
disease MESH congestive heart failure
disease DOID congestive heart failure
disease MESH cardiac arrhythmia
gene UNIPROT REST
drug DRUGBANK Oxygen
drug DRUGBANK Methylprednisolone
disease MESH allergic reaction
disease MESH anaphylaxis
disease DOID hypersensitivity
disease MESH adverse drug reaction
drug DRUGBANK Testosterone
disease MESH men
gene UNIPROT ELL
disease MESH prostate cancer
disease DOID prostate cancer
pathway BSID Prostate cancer
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Carcinoma
disease DOID Carcinoma

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *